Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 182

1.

The genetic evolution of metastatic uveal melanoma.

Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, Weier JF, Wadt K, Heegaard S, Bastian BC, Kiilgaard JF.

Nat Genet. 2019 Jul;51(7):1123-1130. doi: 10.1038/s41588-019-0440-9. Epub 2019 Jun 28.

PMID:
31253977
2.

Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis.

Afshar AR, Damato BE, Stewart JM, Zablotska LB, Roy R, Olshen AB, Joseph NM, Bastian BC.

Transl Vis Sci Technol. 2019 Apr 17;8(2):18. doi: 10.1167/tvst.8.2.18. eCollection 2019 Mar.

3.

Association of Indoor Tanning Exposure with Age at Melanoma Diagnosis and BRAF V600E Mutations.

Burbidge TE, Bastian BC, Guo D, Li H, Morris DG, Monzon JG, Leung G, Yang H, Cheng T.

J Natl Cancer Inst. 2019 Mar 28. pii: djz048. doi: 10.1093/jnci/djz048. [Epub ahead of print]

PMID:
30923800
4.

Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion.

Yeh I, Busam KJ, McCalmont TH, LeBoit PE, Pissaloux D, Alberti L, de la Fouchardière A, Bastian BC.

Am J Surg Pathol. 2019 Jun;43(6):737-746. doi: 10.1097/PAS.0000000000001235.

PMID:
30844834
5.

Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.

Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, Fullen DR, Joseph N, Bastian BC, Patel RM, Martincorena I, Robles-Espinoza CD, Iyer V, Kuijjer ML, Arends MJ, Brenn T, Harms PW, Wood GA, Adams DJ.

Nat Commun. 2019 Jan 21;10(1):353. doi: 10.1038/s41467-018-08081-1.

6.

Targeted genomic profiling of acral melanoma.

Yeh I, Jorgenson E, Shen L, Xu M, North JP, Shain AH, Reuss D, Wu H, Robinson WA, Olshen A, von Deimling A, Kwok PY, Bastian BC, Asgari MM.

J Natl Cancer Inst. 2019 Jan 18. doi: 10.1093/jnci/djz005. [Epub ahead of print]

PMID:
30657954
7.

Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma.

Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, Bell CF, Joseph NM, Wu H, Bastian BC, Zon LI, Yeh I.

Science. 2018 Nov 30;362(6418):1055-1060. doi: 10.1126/science.aau6509. Epub 2018 Nov 1.

8.

Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.

Lee J, Putnam AR, Chesier SH, Banerjee A, Raffel C, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Perry A, Solomon DA.

Acta Neuropathol Commun. 2018 Sep 19;6(1):95. doi: 10.1186/s40478-018-0598-x. No abstract available.

9.

The genetic landscape of gliomas arising after therapeutic radiation.

López GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, Samuel D, Siongco A, Raffel C, Gupta N, Kunwar S, Mummaneni P, Aghi M, Theodosopoulos P, Berger M, Phillips JJ, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA.

Acta Neuropathol. 2019 Jan;137(1):139-150. doi: 10.1007/s00401-018-1906-z. Epub 2018 Sep 8.

10.

Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42.

Stevers M, Rabban JT, Garg K, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Zaloudek C, Solomon DA.

Mod Pathol. 2019 Jan;32(1):88-99. doi: 10.1038/s41379-018-0127-2. Epub 2018 Aug 31.

11.

The tumor suppressor BAP1 cooperates with BRAFV600E to promote tumor formation in cutaneous melanoma.

Webster JD, Pham TH, Wu X, Hughes NW, Li Z, Totpal K, Lee HJ, Calses PC, Chaurushiya MS, Stawiski EW, Modrusan Z, Chang MT, Tran C, Lee WP, Chalasani S, Hung J, Sharma N, Chan S, Hotzel K, Talevich E, Shain A, Xu M, Lill J, Dixit VM, Bastian BC, Dey A.

Pigment Cell Melanoma Res. 2019 Mar;32(2):269-279. doi: 10.1111/pcmr.12735. Epub 2018 Sep 24.

PMID:
30156010
12.

The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, Perry A, Shieh JTC, Solomon DA.

Brain Pathol. 2019 Jan;29(1):85-96. doi: 10.1111/bpa.12639. Epub 2018 Nov 6.

PMID:
30051528
13.

Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile.

Solomon DA, Korshunov A, Sill M, Jones DTW, Kool M, Pfister SM, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Johnston J, Cham E, Cooney T, Sun PP, Oberheim Bush NA, McDermott M, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Villanueva-Meyer JE, Pekmezci M, Bollen AW, Perry A.

Acta Neuropathol. 2018 Aug;136(2):339-343. doi: 10.1007/s00401-018-1883-2. Epub 2018 Jul 13. No abstract available.

PMID:
30006677
14.

Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.

Zeng H, Jorapur A, Shain AH, Lang UE, Torres R, Zhang Y, McNeal AS, Botton T, Lin J, Donne M, Bastian IN, Yu R, North JP, Pincus L, Ruben BS, Joseph NM, Yeh I, Bastian BC, Judson RL.

Cancer Cell. 2018 Jul 9;34(1):56-68.e9. doi: 10.1016/j.ccell.2018.05.014.

15.

Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, Ruben B, North J, Pincus L, Yeh I, Judson R, Bastian BC.

Cancer Cell. 2018 Jul 9;34(1):45-55.e4. doi: 10.1016/j.ccell.2018.06.005.

16.

The genetic landscape of ganglioglioma.

Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA.

Acta Neuropathol Commun. 2018 Jun 7;6(1):47. doi: 10.1186/s40478-018-0551-z.

17.

A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle.

Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, Van Ziffle J, Joseph NM, Onodera C, Talevich E, Grenert JP, Hewedi IH, Snuderl M, Brat DJ, Kleinschmidt-DeMasters BK, Rodriguez FJ, Louis DN, Yong WH, Lopes MB, Rosenblum MK, Butowski N, Tihan T, Bollen AW, Phillips JJ, Wiita AP, Yeh I, Jacobson MP, Bastian BC, Perry A, Solomon DA.

Nat Commun. 2018 Feb 23;9(1):810. doi: 10.1038/s41467-018-02826-8.

18.

Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.

Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA.

Acta Neuropathol. 2018 Apr;135(4):635-638. doi: 10.1007/s00401-018-1819-x. Epub 2018 Feb 12. No abstract available.

19.

Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway.

Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova NM, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, Perry A, Solomon DA.

Acta Neuropathol. 2018 Mar;135(3):485-488. doi: 10.1007/s00401-018-1820-4. Epub 2018 Feb 10. No abstract available.

20.

Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation.

Goode B, Joseph NM, Stevers M, Van Ziffle J, Onodera C, Talevich E, Grenert JP, Yeh I, Bastian BC, Phillips JJ, Garg K, Rabban JT, Zaloudek C, Solomon DA.

Mod Pathol. 2018 Apr;31(4):660-673. doi: 10.1038/modpathol.2017.153. Epub 2017 Nov 17.

21.

Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi.

Yeh I, Lang UE, Durieux E, Tee MK, Jorapur A, Shain AH, Haddad V, Pissaloux D, Chen X, Cerroni L, Judson RL, LeBoit PE, McCalmont TH, Bastian BC, de la Fouchardière A.

Nat Commun. 2017 Sep 21;8(1):644. doi: 10.1038/s41467-017-00758-3.

22.

Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.

Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC, Hockemeyer D.

Science. 2017 Sep 29;357(6358):1416-1420. doi: 10.1126/science.aao0535. Epub 2017 Aug 17.

23.

Filling the gaps in the genomic catalogue of melanoma subtypes.

Shain AH, Bastian BC.

Pigment Cell Melanoma Res. 2017 Jan;30(6):508-509. doi: 10.1111/pcmr.12612. Epub 2017 Oct 21. No abstract available.

PMID:
28656717
24.

RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.

Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC.

Cancer Cell. 2017 May 8;31(5):685-696.e6. doi: 10.1016/j.ccell.2017.04.002.

25.

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn WM, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA.

Neuro Oncol. 2017 May 1;19(5):699-709. doi: 10.1093/neuonc/now254. Erratum in: Neuro Oncol. 2017 Apr 1;19(4):601.

26.

Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study.

Eluri M, Feneran A, Bordeaux JS, Ruben B, Ostrowski S, Bastian BC, Honda K.

JAAD Case Rep. 2017 Mar 20;3(2):131-134. doi: 10.1016/j.jdcr.2017.01.011. eCollection 2017 Mar. No abstract available.

27.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS.

Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079.

28.

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.

Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG.

Sci Rep. 2017 Mar 13;7:44206. doi: 10.1038/srep44206.

29.

Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.

Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA.

Mod Pathol. 2017 Feb;30(2):246-254. doi: 10.1038/modpathol.2016.188. Epub 2016 Nov 4.

30.

Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation.

Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT.

Acta Neuropathol. 2016 Nov;132(5):757-760. Epub 2016 Sep 13. No abstract available.

31.

NTRK3 kinase fusions in Spitz tumours.

Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC.

J Pathol. 2016 Nov;240(3):282-290. doi: 10.1002/path.4775.

32.

Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.

Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, Hosfield E, Yeh I, Talevich E, Onodera C, Van Ziffle JA, Grenert JP, Bastian BC, Chen YY, Krings G.

Mod Pathol. 2016 Sep;29(9):1012-27. doi: 10.1038/modpathol.2016.97. Epub 2016 Jun 3.

33.

From melanocytes to melanomas.

Shain AH, Bastian BC.

Nat Rev Cancer. 2016 Jun;16(6):345-58. doi: 10.1038/nrc.2016.37. Epub 2016 Apr 29. Review.

PMID:
27125352
34.

CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing.

Talevich E, Shain AH, Botton T, Bastian BC.

PLoS Comput Biol. 2016 Apr 21;12(4):e1004873. doi: 10.1371/journal.pcbi.1004873. eCollection 2016 Apr.

35.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

36.

The Genetic Evolution of Melanoma.

Shain AH, Bastian BC.

N Engl J Med. 2016 Mar 10;374(10):995-6. doi: 10.1056/NEJMc1515834. No abstract available.

PMID:
26962740
37.

Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas.

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Yeh I, Bastian BC, Mueller S, Solomon DA.

Neuro Oncol. 2016 May;18(5):752-3. doi: 10.1093/neuonc/now013. Epub 2016 Feb 21. No abstract available.

38.

The Genetic Evolution of Melanoma from Precursor Lesions.

Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D'Arrigo C, Robson A, Bastian BC.

N Engl J Med. 2015 Nov 12;373(20):1926-36. doi: 10.1056/NEJMoa1502583.

39.

Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, Scolyer RA, Cho RJ, Murali R, Bastian BC.

Nat Genet. 2015 Oct;47(10):1194-9. doi: 10.1038/ng.3382. Epub 2015 Sep 7.

40.

A caveolin-dependent and PI3K/AKT-independent role of PTEN in β-catenin transcriptional activity.

Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow F, Bastian BC, Campbell AD, Colombo S, Puig I, Bellacosa A, Sansom O, Marais R, Van Kempen LC, Larue L.

Nat Commun. 2015 Aug 26;6:8093. doi: 10.1038/ncomms9093.

41.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

42.

Congenital uveal melanoma?

Singh AD, Schoenfield LA, Bastian BC, Aziz HA, Marino MJ, Biscotti CV.

Surv Ophthalmol. 2016 Jan-Feb;61(1):59-64. doi: 10.1016/j.survophthal.2015.07.005. Epub 2015 Aug 12. Review.

PMID:
26277063
43.

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV.

Pigment Cell Melanoma Res. 2015 Sep;28(5):607-10. doi: 10.1111/pcmr.12388. Epub 2015 Jul 3. No abstract available.

44.

Activating MET kinase rearrangements in melanoma and Spitz tumours.

Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC.

Nat Commun. 2015 May 27;6:7174. doi: 10.1038/ncomms8174.

45.

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.

Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud AI.

Br J Cancer. 2015 Apr 14;112(8):1326-31. doi: 10.1038/bjc.2014.541. Epub 2015 Mar 31.

46.

Peri-operative Levosimendan in Patients Undergoing Cardiac Surgery: An Overview of the Evidence.

Shi WY, Li S, Collins N, Cottee DB, Bastian BC, James AN, Mejia R.

Heart Lung Circ. 2015 Jul;24(7):667-72. doi: 10.1016/j.hlc.2015.03.007. Epub 2015 Mar 24. Review.

PMID:
25862519
47.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

48.

Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.

Yeh I, de la Fouchardiere A, Pissaloux D, Mully TW, Garrido MC, Vemula SS, Busam KJ, LeBoit PE, McCalmont TH, Bastian BC.

Am J Surg Pathol. 2015 May;39(5):581-91. doi: 10.1097/PAS.0000000000000387.

49.

Melanoma BRAF fusions--letter.

Botton T, Yeh I, Bastian BC.

Clin Cancer Res. 2014 Dec 15;20(24):6631. doi: 10.1158/1078-0432.CCR-14-0058. No abstract available.

50.

Regulatory network decoded from epigenomes of surface ectoderm-derived cell types.

Lowdon RF, Zhang B, Bilenky M, Mauro T, Li D, Gascard P, Sigaroudinia M, Farnham PJ, Bastian BC, Tlsty TD, Marra MA, Hirst M, Costello JF, Wang T, Cheng JB.

Nat Commun. 2014 Nov 25;5:5442. doi: 10.1038/ncomms6442.

Supplemental Content

Loading ...
Support Center